Inclusion Criteria:

For Study Registration:

- Age 55 - 70 years.

- Subjects diagnosed with AML (> 20% myeloblasts).

For Proceeding to Transplant:

- Subjects must be in either complete remission (CR) or partial remission (PR) within
14 days prior to admission.

- Subjects must be > 21 days since completion of prior systemic chemotherapy or
radiation therapy (including craniospinal XRT), prior to admission .

- Organ function requirements for a reduced intensity (FluBu2) regimen (must be met
within 21 days of admission):

- Cardiac: LV Ejection Fraction > 40% on MUGA or Echocardiogram.

- Pulmonary: FEV1 and FVC > 40% predicted, DLCO > 40% of predicted.

- Renal: Serum creatinine < 2.0 mg/dl. Not on hemodialysis or continuous
veno-venous filtration (CVVH).

- Hepatic: serum total bilirubin < 3.0 mg/dl and AST / ALT < 4x ULN

- Karnofsky > 60%.

- Organ function requirements for a full intensity (FluBu4) regimen (must be met within
21 days of admission):

- Cardiac: LV Ejection Fraction > 40% on MUGA or Echocardiogram.

- Pulmonary: FEV1 and FVC > 50% predicted, DLCO (corrected for hemoglobin) >
50% of predicted.

- Renal: serum creatinine < 2.0 mg/dl. Not on hemodialysis or continuous
veno-venous filtration (CVVH)

- Hepatic: serum total bilirubin < 3.0 mg/dl and AST / ALT < 4x ULN.

- Karnofsky > 60%.

Exclusion Criteria:

For Study Registration:

- Subjects with M3 AML (FAB classification)

For Proceeding to Transplant:

- Subjects who exhibit signs of progressive disease (> 20% blasts) within 14 days prior
to admission for transplant

- Patients with an uncontrolled viral or fungal infection within the prior 28 days.

- Patients who are HIV1 or HIV2 positive.

- Uncontrollable medical or psychiatric disorder